Impact of PET staging in limited-stage small-cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 7, 2013, Pages 899-905

  Xanthopoulos, Eric P ^a   Corradetti, Michael N ^a   Mitra, Nandita ^a   Fernandes, Annemarie T ^a   Kim, Miranda ^a   Grover, Surbhi ^a   Christodouleas, John P ^a   Evans, Tracey L ^a   Stevenson, James P ^a   Langer, Corey J ^a   Lee, Tony T ^b   Pryma, Daniel A ^a   Lin, Lilie L ^a   Simone II, Charles B ^a   Apisarnthanarax, Smith ^a   Rengan, Ramesh ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Chemoradiation; Positron emission tomography; Positron emission tomography computed tomography; Radiation; Small cell lung cancer; Stage migration; Staging

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; BRAIN RADIATION; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 84880916430     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31828e8996     Document Type: Article

References (22)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544.
2. Thomson D, Hulse P, Lorigan P, Faivre-Finn C. The role of positron emission tomography in management of small cell lung cancer. Lung Cancer 2011;73:121-126.
3. Medicare National Coverage Determinations Manual. Chapter 1, part 4. In: Services DoHaH (Ed.), Centers for Medicare and Medicaid Services, 2012, pp 200-300.
4. Seidenfeld JS, Samson DJ, Bonnell, C, Ziegler, KM, Aronson, N. Management of small cell lung cancer. In: Services USDoHaH (Ed.), Washington, D.C.: Agency for Healthcare Research and Quality (AHRQ), 2006.
5. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-1608.
6. Scrucca LS, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marr Transpl 2007;40: 381-87.
7. Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003;44:1911-1917.
8. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004;22:3248-3254.
9. Senan S, De Ruysscher D. Critical review of PET-CT for radiotherapy planning in lung cancer. Crit Rev Oncol Hematol 2005;56:345-351.
10. Shen YY, Shiau YC, Wang JJ, Ho ST, Kao CH. Whole-body 18F-2- deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res 2002;22(2B):1257-1264.
11. Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol 2004;27:164-171.
12. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imag 2004;31:1614-1620.
13. Ung Y GK, Sun R, et al. An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): predictors of overall survival. J Clin Oncol 29: 2011 (supp; abstr 7018) 2011.
14. Using FDG-PET during radiation therapy in non-small cell lung cancer, (HUM15709). University of Michigan Cancer Center. ClinicalTrials.gov identifier NCT01190527. Recruiting as of March 22, 2011.
15. Study of positron emission tomography and computed tomography in guiding radiation therapy in patients with stage III non-small cell lung cancer. National Cancer Institute (NCI). ClinicalTrials.gov identified NCT01507428. Recruiting as of March 26, 2013.
16. Study using induction chemotherapy and intensity-modulated radiation therapy guided by combined CT and PET imaging for patients with nonsmall cell lung cancer. Alberta Health Services. ClinicalTrials.gov identifier NCT00128999. Completed February 8, 2010.
17. Study of 18F-fluorodeoxyglucose (FluGlucoScan) in patients receiving a treatment planning study of 3 dimensional conformal radiation therapy guided by breath held CT and PET imaging for patients with non-small cell lung cancer. Alberta Health Services. ClinicalTrials.gov identifier NCT00123747 Completed March 15, 2012.
18. Kawahara M, Fukuoka M, Saijo N, et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jap J Clin Oncol 1997;27(3): 158-65.
19. Thatcher N, Anderson H, Burt P, Stout R. The value of anatomic staging and other prognostic factors in small cell lung cancer management: a view of European studies. Semin Radiat Oncol 1995;5:19-26.
20. Gayed I, Vu T, Johnson M, Macapinlac H, Podoloff D. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 2003;5:26-31.
21. Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317-325.
22. Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers JS. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer 2008;9:30-34.